

## ColoSTAT<sup>®</sup> abstract accepted for presentation at 2023 ASCO Annual Meeting

### Highlights

- ✓ The 2023 ASCO (American Society of Clinical Oncology) Annual Meeting is one of the premier events for cancer experts globally; and
- ✓ Two abstracts detailing clinical data of ColoSTAT<sup>®</sup> and the economics for its use within the USA.

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) is pleased to announce that both abstracts it submitted on ColoSTAT<sup>®</sup> at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) have been accepted. The abstracts outlining the clinical data and the economics for its adoption in the USA, which will be available to an expected attendance of more than 40,000 healthcare professionals in the event.

The event showcases the latest innovations in cancer research and education, and is being held in Chicago, Illinois from 2-6 June 2023. The abstract detailing ColoSTAT<sup>®</sup> clinical data has been selected out of more than 6,500 submissions reviewed by the Scientific Program Committee and ASCO's Leadership team for presentation at a poster session.

The details of the abstract, to be presented as part of the Gastrointestinal Cancer – Colorectal and Anal session, are:

**Title:** A prospective, cross-sectional, multicentre study to evaluate the clinical performance of the ColoSTAT<sup>®</sup> in vitro diagnostic for the detection of biomarkers associated with colorectal cancer.

**Abstract #:** 3529.

**Session date/time:** 5 June 2023, 8am-11am.

**Title:** Cost-effectiveness of ColoSTAT<sup>®</sup> for primary colorectal cancer screening in the United States.

**Session date/time:** Publication only.

More information on the event can be viewed at: <https://conferences.asco.org/am/attend>

Commenting on the acceptance of the Company's ASCO submissions, **Rhythm Chief Commercial Officer, Ms Elena Deak, commented:**

*"Only a select number of abstracts submitted to ASCO are accepted for presentation at this prestigious event, therefore the team is proud to receive such deserved recognition from a leading organisation in cancer research and innovation.*

*We look forward to highlighting ColoSTAT<sup>®</sup> and the potential outcomes that could result from such exposure."*

- ENDS -

**Authorised for release by the Board.**

**For further information contact:**

Glenn Gilbert  
CEO and Managing Director  
+61 3 8256 2880

**About Rhythm Biosciences**

Rhythm Biosciences is focused on becoming a globally significant, transformative, predictive diagnostics company, specialising in cancer detection technology. The Company is currently developing ColoSTAT® - a simple, low-cost, blood test for global mass market detection of colorectal cancer.

Worldwide, colorectal cancer is the third most common cancer in men and the second most common in women, accounting for an estimated 1.9 million new cases and 935,000 deaths annually.

In an effort to reduce the global burden, many countries have implemented screening programs aimed at early detection. These programs are predominantly administered with a faecal immunochemical test (FIT) for the assessment of colorectal cancer risk, with a positive result referred for a colonoscopy. FIT only analyses the presence of blood in faeces, which can occur for several reasons other than cancer, therefore it is not designed as an accurate test for cancer. Many people simply don't take the test for fear of an unnecessary colonoscopy procedure, unpleasantness, difficulty, or for religious/cultural reasons. There is currently no appropriate blood test alternative.

Rhythm aims to transform the global mass-market for colorectal cancer detection with ColoSTAT® its simple, low-cost blood test that is fit for purpose, meaning that it is designed to actually detect colorectal cancer. Since listing on the ASX in 2017, the Company has run a successful multi-year research and development program that has delivered technical validation of the core biomarker technology, being reproducible and stable. The ColoSTAT® test-kit was manufactured in 2021 and delivered performance testing that outperforms the current market standard faecal immunochemical test utilising Rhythm's proprietary algorithm. The Company is progressing regulatory, manufacturing and scale up activities ahead of market entry in FY23.

ColoSTAT® is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT® has the potential to play a key role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Rhythm's initial targeted global addressable population is over 800 million people which are over 50 years of age. Almost 70%, or 550 million people, are not currently screened for colorectal cancer due to the limitations of the current faecal based testing regime. This "at risk" population is also expanding with the disease growing rapidly in much younger age groups. Early detection and intervention can lead to cure in over 90 per cent of new cases, therefore the need for effective screening and early intervention has the potential to save a significant number of lives. Rhythm estimates today's colorectal cancer screening market alone to be worth in excess of \$38 billion.